SYMBOL: SV
Company: Spring Valley Acquisition Corp.
Company: Spring Valley Acquisition Corp.
SYMBOL
: SVStage: 2. Seeking Target
Size:
Latest Price:
Previous close:
All time high price:
Volume:
Average volume:
FOLLOW SPAC
DISCOVER NEW FRIENDS
GET AHEAD OF THE GAME
Spring Valley Acquisition Corp. is listed on the stock exchange with the ticker / Symbol SV,
SV SPAC all time high was and the lowest price in the last 52 week was: ,
the current SV stock price is . SV has an overall market cap of: .
The latest volume was: .
SV is currently in stage: 2. Seeking Target.
You can read all about SV and it’s information about the SPAC, news, SEC filings and more on our special data platform.
Want to know more about SV and Spring Valley Acquisition Corp.? Join us today.
SV SPAC all time high was and the lowest price in the last 52 week was: ,
the current SV stock price is . SV has an overall market cap of: .
The latest volume was: .
SV is currently in stage: 2. Seeking Target.
You can read all about SV and it’s information about the SPAC, news, SEC filings and more on our special data platform.
Want to know more about SV and Spring Valley Acquisition Corp.? Join us today.
- Motion sensing startup Movella plans merger with Pathfinder Acquisition blank check company – Silicon Valley Business Journal – The Business Journals
- Chasing Biogen and Sage, Eliem hustles depression drug into phase 2 after clearing up PK question – FierceBiotech
- Startup Funding: September 2022 – SemiEngineering
- Kinarus stops midphase study in hospitalized COVID-19 patients early, adding to long list of failed trials – FierceBiotech
- Biohaven veers toward Kv7 platform following Pfizer sale – FierceBiotech
- SyntheX ropes in BMS for molecular glue degrader discovery – FierceBiotech
- PACT unveils teased business venture, sells off select assets to AmplifyBio – FierceBiotech
- Pfizer, AstraZeneca, Merck KGaA-backed Israeli AI incubator launches first biopharma startup – FierceBiotech
- SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route – FierceBiotech
- VC firm LifeArc sells first portfolio company as dermatitis-focused Ducentis bought by Arcutis for $30M – FierceBiotech
- Rise of the machines: Novo Nordisk Foundation pledges $200M to create first quantum computer for life sciences – FierceBiotech
- Incyte scoops up preclinical biotech to widen footprint in vitiligo – FierceBiotech
- Clene's shares slump some 34% on phase 2 ALS flop – FierceBiotech
- Mesoblast keeps hopes of cell therapy approval alive in latest response to FDA – FierceBiotech
- Q3 2022 News Roundup – Payload – Payload
